Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Part of paid clinical trials in New York, New York.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT00045604
- Phase
- PHASE1
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- cisplatin — DRUG
- imatinib mesylate — DRUG
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining imatinib mesylate with irinotecan and cisplatin in treating patients who have extensive-stage small cell lung cancer
Key Dates
- Start date
- Jul 31, 2002
- Status verified
- Apr 2004
Study Design
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10021 | - |
Find similar trials in New York, NY
By condition
By specialty
By research site
Related Studies
- Lung Cancer Biomarkers and ScreeningRecruiting · NYU Langone Health · New York, New York
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®PHASE2 · Recruiting · CivaTech Oncology · New York, New York
- WTC Chest CT Imaging ArchiveEnrolling By Invitation · Icahn School of Medicine at Mount Sinai · New York, New York